author-photo

Balázs Szalay

Semmelweis University
Hungarian Academy of Sciences

54

Papers

527

Citations

Citation Trend

Filter By

Papers (42) Sort By

Journal Conference Others

Cytokine profile in SARS-CoV-2 infection and the effect of tocilizumab and convalescent plasma therapy

2021 Clinical Chemistry and Laboratory Medicine
Show All
- Source
- Cite
- Save
Citations (0)
Urine soluble urokinase plasminogen activator receptor as a potential biomarker of lupus nephritis activity.

2021 Biomarkers
Show All
- Source
- Cite
- Save
Citations (2)
EDTA-Induced Pseudothrombocytopenia Up to 9 Months After Initial COVID-19 Infection Associated with Persistent Anti-SARS-CoV-2 IgM/IgG Seropositivity.

2021 Labmedicine
Show All
- Source
- Cite
- Save
Citations (0)
Vitamin D Deficiency has no Impact on PSA Reference Ranges in a General University Hospital - A Retrospective Analysis.

2020
Show All
- Source
- Cite
- Save
Citations (0)
Outcomes of Patients With Inflammatory Bowel Diseases Switched From Maintenance Therapy With a Biosimilar to Remicade

2019 Clinical Gastroenterology and Hepatology
Show All
- Source
- Cite
- Save
Citations (16)
Mo1892 – Non-Medical Reverse Switch Between the Originator Infliximab and Its Biosimilar in Patients with Inflammatory Bowel Disease: Clinical Outcomes and Therapeutic Drug Monitoring

2019 Gastroenterology
Show All
- Source
- Cite
- Save
Citations (1)
The Impact of Anti-TNF Therapy on CD4+ and CD8+ Cell Subsets in Ankylosing Spondylitis

2018 Pathobiology
Show All
- Source
- Cite
- Save
Citations (11)
Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide Cohort

2017 Inflammatory Bowel Diseases
Show All
- Source
- Cite
- Save
Citations (30)
P592 Final results on immunogenicity profile and predictors of ADA development of biosimilar infliximab during the first 12 months of the therapy: results from a prospective nationwide cohort

2017 Journal of Crohns & Colitis
Show All
- Source
- Cite
- Save
Citations (2)
Final Results on Immunogenicity Profile and Predictors of ADA Development of Biosimilar Infliximab During the First 12 Months of the Therapy: Results from a Prospective Nationwide Cohort

2017 Gastroenterology
Show All
- Source
- Cite
- Save
Citations (0)